BiotechTube

Inotersen

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

FAP

Conditions

FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis

Trial Timeline

Jun 26, 2014 → Jan 7, 2021

NCT ID
NCT02175004

About Inotersen

Inotersen is a phase 3 stage product being developed by Ionis Pharmaceuticals for FAP. The current trial status is completed. This product is registered under clinical trial identifier NCT02175004. Target conditions include FAP, Familial Amyloid Polyneuropathy, TTR.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT03400098Pre-clinicalCompleted
NCT02175004Phase 3Completed

Competing Products

2 competing products in FAP

See all competitors
ProductCompanyStageHype Score
CelecoxibPfizerPre-clinical
22
Inotersen + PlaceboIonis PharmaceuticalsPhase 2/3
62

Other Products from Ionis Pharmaceuticals

ISIS 3521 + carboplatin + paclitaxelPhase 3
74
DonidalorsenPhase 3
74
mipomersen sodium + placeboPhase 3
74
Olezarsen + PlaceboPhase 3
74
ION582 + PlaceboPhase 3
74